SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical ...

PDIGREE phase III adaptive, enrolled 1000+ metastatic kidney cancer patients across 500+ sites, ASCO 2025 results and innovative treatment strategies, PDIGREE Trial Tests Adaptive Immunotherapy ...

February 19, 2025 Prostate specific membrane antigen (PSMA) PET scans recently gained approval from the United States FDA in 2020 for staging newly diagnosed prostate cancer. Given the increased ...

CONTACT-03 subset analysis, cabozantinib efficacy regardless of prior IO-IO or IO-TKI treatment, ASCO insights on kidney cancer sequencing, CONTACT-03 Subset Analysis: Similar Cabozantinib Response ...

Zachary Klaassen hosts Alessandro Viti to discuss early oncological outcomes in very high-risk prostate cancer patients using PSMA-PET imaging. Dr. Viti addresses the research question of how surgery ...

Andrea Miyahira speaks with Salomon Tendler about his work targeting neuroendocrine prostate cancer (NEPC), an aggressive castration-resistant form affecting 15-20% of advanced prostate cancer ...

UroToday's exclusive Video Lecture content covering Advanced Prostate Cancer.

Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. July 18, 2025 Unplanned hospitalization among advanced prostate cancer patients by diabetes status-a ...

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC CG Oncology, Inc.